Alexis N. Thompson
Elite in Anemia

Dr. Alexis N. Thompson

Intensive Care Medicine | Pediatrics
Baltimore, MD 
38 Years of Experience
Elite in Anemia
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexis Thompson is a Pediatrics specialist and an Intensive Care Medicine provider in Baltimore, Maryland. Dr. Thompson has been practicing medicine for over 38 years and is rated as an Elite provider by MediFind in the treatment of Anemia. Her top areas of expertise are Anemia, Infantile Neutropenia, Exocrine Pancreatic Insufficiency, Immune Thrombocytopenic Purpura (ITP), and Splenectomy.

Her clinical research consists of co-authoring 145 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 127 articles and participated in 5 clinical trials in the study of Anemia.

Residency
Rhode Island Hospital, Pediatrics, 2021
Specialties
Intensive Care Medicine
Pediatrics
Licenses
Anesthesiology in MD
Board Certifications
American Board Of Pediatrics
Fellowships
Johns Hopkins University School of Medicine, Pediatric Critical Care Medicine, 2024
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

The Johns Hopkins Hospital
Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drugs: Eltrombopag, Steroids, IVIg, Rho(D) Immune Globulin
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
Engaging Parents of Children With Sickle Cell Anemia and Their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU)
Engaging Parents of Children With Sickle Cell Anemia and Their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU)
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drugs: Eltrombopag, Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
Enrollment Status: Completed
Publish Date: December 18, 2024
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Deferasirox
Study Phase: Phase 2
Pyruvate Kinase Deficiency (PKD) Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Enrollment Status: Completed
Publish Date: May 22, 2020
View 7 Less Clinical Trials

145 Total Publications

Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.
Journal: JAMA
Published: October 22, 2025
Similar Doctors
Ambroise Wonkam
Elite in Anemia
Dr. Ambroise Wonkam
Pediatrics | Medical Genetics
Elite in Anemia
Dr. Ambroise Wonkam
Pediatrics | Medical Genetics

Rubenstein Child Health Building

Baltimore, MD 
 (1.2 miles away)
443-287-9494
Languages Spoken:
English, French
See accepted insurances

Ambroise Wonkam is a Pediatrics specialist and a Medical Genetics provider in Baltimore, Maryland. Dr. Wonkam is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Anemia, Fragile X Syndrome, Pyle Disease, and Micrognathia.

Distinguished in Anemia
Dr. Emily M. Limerick
Pediatrics
Distinguished in Anemia
Dr. Emily M. Limerick
Pediatrics
11125 Rockville Pike, Suite 307, 
Rockville, MD 
 (32.9 miles away)
301-468-6171
Languages Spoken:
English

Emily Limerick is a Pediatrics provider in Rockville, Maryland. Dr. Limerick is rated as a Distinguished provider by MediFind in the treatment of Anemia. Her top area of expertise is Anemia.

Advanced in Anemia
Dr. Zenaide Quezado
Intensive Care Medicine
Advanced in Anemia
Dr. Zenaide Quezado
Intensive Care Medicine

Children's National Hospital

111 Michigan Ave NW, 
Washington, DC 
 (34.2 miles away)
202-884-2025
Languages Spoken:
English
See accepted insurances

Zenaide Quezado is an Intensive Care Medicine provider in Washington, Washington, D.c.. Dr. Quezado is rated as an Advanced provider by MediFind in the treatment of Anemia. Her top areas of expertise are Anemia, Acute Pain, and Autism Spectrum Disorder.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thompson's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile